Lifecore Biomedical
LFCR
99 hedge funds and large institutions have $258M invested in Lifecore Biomedical in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 11 closing their positions.
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
9% more funds holding
Funds holding: 91 → 99 (+8)
4.03% more ownership
Funds ownership: 90.21% → 94.24% (+4%)
20% less capital invested
Capital invested by funds: $323M → $258M (-$65.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$15.9M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$8.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$2.08M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.1M |
| 2 |
RA
Royce & Associates
New York
|
-$5.34M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.67M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.5M |
| 5 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$2.17M |
LFCR Hedge Fund Activity: Q2 2019 in Review
99 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2019, worth a combined $258M — down 20% from $323M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LFCR positions and 11 closed out — a net gain of 10 holders — while 33 added to existing stakes and 25 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $15.9M. The largest seller was Franklin Resources, cutting an estimated $12.1M.
- 99 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2019, up from 91 in Q1 2019.
- Funds reported $258M of Lifecore Biomedical stock for Q2 2019, down 20% quarter-over-quarter.
- 21 funds opened new Lifecore Biomedical positions in Q2 2019 and 11 closed out, a net change of +10 holders.
- The largest Lifecore Biomedical buyer in Q2 2019 was Russell Investments Group, an estimated $15.9M added.
- The largest Lifecore Biomedical seller in Q2 2019 was Franklin Resources, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2019.